Biosyngen’s BST02 Receives the US FDA’s Fast Track Designation to Treat Liver Cancer
Shots:
- The US FDA has granted FTD to the company’s BST02 for treating multiple types of liver cancer such as hepatocellular carcinoma and cholangiocarcinoma
- BST02 is currently being evaluated in a P-I/II dose escalation & expansion study for its safety, tolerability, and initial efficacy for the treatment of locally advanced/metastatic liver cancer
- The company’s BST02 is a T-cell therapy that employs the patient's own tumor infiltrating lymphocytes and has the potential of overcoming distance constraints because of its cryopreserved form and the reduced need for high interleukin-2 dosage
Ref: Biosyngen | Image: Biosyngen
Related News:- BioCity Collaborated with AstraZeneca to Evaluate BC3402 + Imfinzi (durvalumab) for Advanced Hepatocellular Carcinoma in China
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Shivani is a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
